Table 1.

Characteristics of patients with Behcet’s disease (N = 53).

	Non-arthritis group	Arthritis group	p-value
Number of cases	27	26
Age, year	49.7 ± 13.8	48.5 ± 12.9	0.7351
Female, n(%)	17 (63.0)	21 (80.8)	0.1471
Disease duration, year	14.3 ± 10.7	12.0 ± 7.6	0.5324
HLA-B51 positive, n(%)	9 (52.9), n = 17	6 (33.3), n = 18	0.2399
HLA-A26 positive, n(%)	4 (26.7), n = 15	8 (50.0), n = 16	0.1794
Major lesions ever observed
Oral ulcer, n(%)	27 (100)	26 (100)	-
Genital ulcer, n(%)	24 (88.9)	23 (88.5)	1.0000
Skin lesion, n(%)	23 (85.2)	24 (92.3)	0.6687
Erythema nodosum, n(%)	17 (63.0)	12 (46.2)	0.2729
Thrombophlebitis, n(%)	2 (7.4)	2 (7.7)	1.0000
Papulopustular skin lesions, n(%)	20 (74.1)	23 (88.5)	0.2935
Arthritis, n(%)	18 (66.7)	26 (100)	0.0018*
Eye involvement, n(%)	9 (33.3)	7 (26.9)	0.7664
Epididymitis, n(%)	3 (11.1)	1 (3.9)	0.6104
Gastrointestinal involvement, n(%)	3 (11.1)	4 (15.4)	0.7040
Nervous system involvement, n(%)	5 (18.5)	4 (16.0)	1.0000
Vascular involvement, n(%)	0 (0)	2 (7.7)	0.2358
Medication, n(%)
NSAIDs	1 (3.7)	5 (19.2)	0.0642
Colchicine	19 (70.4)	17 (65.4)	0.6974
Glucocorticoids	8 (29.6)	10 (38.5)	0.4970
Dose, median(IQR), mg/d	2.5 (2.1, 5.0)	3.5 (2.0, 5.0)	0.8906
Methotrexate	2 (7.4)	7 (7.7)	0.9687
Azathioprine	1 (3.7)	0 (0)	0.2423
Cyclosporine	1 (3.7)	0 (0)	0.2423
Tumor necrosis factor inhibitors	3 (11.1)	4 (15.4)	0.6456
Apremilast	6 (22.2)	4 (15.4)	0.5234
5-aminosalicylic acid	0 (0)	3 (11.5)	0.0347*
Duration of current treatment, month	51.7 ± 70.2	36.8 ± 48.5	0.9708
Arthritis activity
SDAI, median(IQR)	-	9.7 [5.9–12.7]	-
CDAI, median(IQR)	-	9.4 [5.9–12.0]	-
DAS28-CRP, median(IQR)	-	2.8 [2.3–3.4]	-

SDAI: Simplified disease activity index, CDAI: Clinical disease activity index, DAS: Disease activity score.

p-values were determined by the Mann-Whitney U test, Fisher’s exact test, or chi-square test.

*Data were considered significant at p < 0.05.